This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Promethera Biosciences S.a./n.v., Promethera Therapeutics Sa. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2022
Title: The Innovative Contributions of Sarah Snykers
Introduction
Sarah Snykers is a prominent inventor based in Lede, Belgium. She has made significant strides in the field of biotechnology, particularly in the development of adult liver progenitor cells. With a total of 3 patents to her name, Snykers is recognized for her innovative approaches to addressing liver diseases.
Latest Patents
One of her latest patents is a method for producing adult liver progenitor cells, known as H2Stem Cells. These novel cells have been characterized based on a series of biological activities and markers. The methods developed for producing H2Stem Cells allow for the provision of these cells in the form of adherent cells and three-dimensional cell clusters in suspension. These cells can be differentiated into liver-specific cells that possess strong activities, making them valuable for treating liver diseases or for evaluating the efficacy, metabolism, and toxicity of various compounds.
Career Highlights
Throughout her career, Sarah Snykers has worked with notable companies in the biotechnology sector, including Promethera Biosciences and Promethera Therapeutics. Her work has contributed to advancements in regenerative medicine and cellular therapies.
Collaborations
Snykers has collaborated with esteemed colleagues such as Etienne Sokal and Tuba Baran, further enhancing her research and development efforts in the field.
Conclusion
Sarah Snykers is a trailblazer in the field of biotechnology, with her innovative patents and collaborations paving the way for future advancements in liver disease treatment. Her contributions continue to impact the scientific community and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile